InterMune, Inc. (NASDAQ:ITMN)

CAPS Rating: 2 out of 5

The Company is a biotech company focused on developing and commercializing innovative therapies in pulmonology and hepatology.

Recs

0
Player Avatar Biotech2010 (87.49) Submitted: 1/26/2010 8:56:24 PM : Underperform Start Price: $14.13 ITMN Score: +45.07

13.47

Report this Post Reply

Featured Broker Partners


Advertisement